b-thalassemia major is a genetic disorder resulting in absent or reduced b globin chain synthesis producing hemolytic anemia. Currently, the only cure for thalassemia is allogeneic stem cell transplantation, which corrects the genetic defect in the hematopoietic system by the use of allogeneic stem cells. According to Pesaro classification, patients with thalassemia major can be categorized into three classes of risk for marrow transplantation, and patients with class 3 who had evidence of organ damage from iron-overload had poor outcomes, and were more likely to experience transplant-related mortality or disease recurrence. One approach to reduce transplant-related mortality is to use reduced-intensity stem cell transplantation (RIST) and here we report the successful transplantation from 6/6 matched unrelated donors using reduced-intensity conditioning for two children with class 3 thalassemia major who had evidence of organ damage.
The conditioning regimen was composed of cyclophosphamide (50 mg/kg once daily i.v. on days À4, À3, À2 and À1), busulfan (2 mg/kg/day on days À8, À7, À6 and À5, total dose 8 mg/kg), fludarabine (30 mg/m 2 once daily i.v. on days À4, À3, À2 and À1), rabbit antithymocyte globulin (Fresenius, Grafelfing, Germany) (10 mg/kg once daily i.v. on days À4, À3, À2 and À1). As GVHD prophylaxis, patients received cyclosporine (3 mg/kg/day i.v. by continuous infusion from day À1), and methotrexate (10 mg/m 2 i.v. on day þ 1, þ 3 and þ 6). The dose of CSA was tapered from day 60 until discontinuation on day þ 180. Mycophenolate mofetil (MMF) was administered from day À1 to day þ 30 (15 mg/kg, p.o. B.i.d.).
Patient no. 1 was a 9-year-old boy with homozygous b-thalassemia who had received monthly transfusion since 5 months of age and never received chelation therapy with desferrioxamine. Prior to transplant, his ferritin level was 10180.85 mg/l, and ALT and AST were 133 U/l and 113 U/l, respectively. His liver was palpable 6 cm below costal margin and his spleen was palpable 3 cm below costal margin. A liver biopsy was performed which revealed hepatic fibrosis. The graft contained 17.1 Â 10 8 /kg mononuclear cells, and 12.5 Â 10 6 /kg CD34 þ cells. The early post transplant course was complicated by delayed massive immune hemolysis mediated by 'passenger' lymphocytes and serum testing showed the presence of anti-A and anti-B antibodies. Prompt engraftment with absolute neutrophil count 40.5 Â 10 9 /l, and platelet count 420 Â 10 9 /l was observed on days þ 13 and þ 30. The proportion of donor cells in the recipient's blood was 100% on day þ 30. The patient developed chronic GVHD on day þ 150, presenting mainly with skin rash and oral ulceration, (which gradually subsided with the initiation of prednisone) and repeated pulmonary infections. Iron overload was treated with a phlebotomy, starting on day þ 120, every two weeks. At 1 year after transplant, the patient was still 100% donor and had no clinical features of thalassemia, although his cardiac and pulmonary functions were still slightly decreased, and his Karnofsky score was 90. Hemoglobin level was 12 g/dl, but ferritin was still elevated at 9465.6 mg/l.
Patient no.2 was a 5-year-old girl with homozygous betathalassemia who had received monthly transfusion since 6 months of age and never received chelation therapy with desferrioxamine. Prior to transplant, her ferritin level was 7485.25 mg/l, and ALT and AST were 68 U/l and 76 U/l, respectively. Her liver was palpable 3 cm below costal margin and her spleen was palpable 2 cm below costal margin. A liver biopsy was performed which revealed hepatic fibrosis. The graft contained 11.8 Â 10 8 /kg mononuclear cells, and 5.9 Â 10 6 /kg CD34 þ cells. Prompt engraftment with absolute neutrophil count 40.5 Â 10 9 /l, and platelet count 42.0 Â 10 9 /l was observed on days þ 13 and þ 18. The proportion of donor cells in the recipient's blood was 100% on day þ 30. Iron overload was treated with a phlebotomy, starting on day þ 120, every two weeks. At 2 years after transplant, the patient had no clinical features of thalassemia, and her cardiac and pulmonary functions were normal, and a Karnofsky score of 100. Hemoglobin was 12.5 g/dl, and the ferritin level had decreased to 3979.75 mg/l. She remained 100% donor.
Lucarelli et al.
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reported that the probabilities of thalassemia-free survival: cumulative incidence of rejection, and nonrejection mortality were, respectively, 58, 30, and 18% in 122 consecutive patients with class 3 thalassemia who were prepared with a regimen of busulfan (BU) 14 mg/kg followed by cyclophosphamide (CY) 120 or 160 mg/kg. One option for class 3 patients who had been tested in limited clinical series is reduced-intensity stem cell transplantation, which relies upon immunosuppressive rather than ablative transplantation conditioning to facilitate engraftment of donor cells. One of the major concerns with this strategy is that a reduction in myeloablation will increase the risk of graft rejection since it was once considered that ablation of all host stem cells was required to establish conditions for complete marrow engraftment of donor cells. Fludarabine, a purine nucleoside analogue that requires intracellular phosphorylation to its biologically active form, has been shown to manifest both myeloablative and immunosuppressive activity in hematological malignancies. Owing to its immunosuppressive potency and additional myeloablation, fludarabine has been included into nonmyeloablative conditioning regimen for nonmalignant disease. 2 Slavin et al. 3 first reported a successful transplantation from related donor using nonmyeloablative conditioning for thalassemia major, followed by a case report by Hongeng et al., 4 in which a 10-year-old girl who had class 3 thalassemia major was successfully transplanted with graft from sibling donor using nonmyeloablative regimen. However, as to our knowledge, there has been no experience with reducedintensity conditioning in children with thalassemia major undergoing unrelated donor transplantation. The reducedintensity regimen presented in this report appears to be well tolerated, leading to durable engraftment. We assumed that the regimen may be not powerful enough to eradicate the hematopoietic system of thalassemic patients, but relies on its graft-versus-host effect mediated by donor T-cells to eradicate the thalassemic clone and maintain durable engraftment.
